Ann: Cynata to Present at ISCT Meeting, page-5

It was self deprecating humour Pledge. You should try it some time. No CYP investors are seriously expecting Sumitomo to revisit its former $2 or more accurately $200 million takeover. But a Novartis door knock would be nice. The expectation and discussion was a commercial partnership in an area of pressing need that sees some 4,400 amputations and 1,700 deaths in Australia alone.

Stop pumping CYP Pledge with all this take over talk. Any partnership, would likely be far short of $2 or $200 million takeover, but indeed invaluable in the long term business of CYP if it did eventuate.